Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

12.3% CAGR, Circulating Tumor Cells Market to Reflect US$ 9.85 Billion by 2030: Reports Insights

Published

on

<!– Name:DistributionId Value:8777173 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1265965 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:56011922-eb03-4830-865d-5b33bbc27cb3 –>

New York, Feb. 27, 2023 (GLOBE NEWSWIRE) — The Circulating Tumor Cells (CTC) Market is projected to grow at a CAGR of 12.3% from 2023 to 2030, with a value of USD 9.85 Billion by 2030, according to the research report by Reports Insights. The market was valued at USD 3.89 Billion in 2022. The report analyzes the market by segmenting it into different components such as product type, technology, application, end-user, and region. It provides a detailed analysis of the competitive landscape of the market, including key players, their strategies, and market share.

The inclusive market research report on the circulating tumor cells market is offered by Reports Insights Pvt. Ltd.  The research provides an in-depth analysis of macroeconomic statistics such as market dynamics, segmental analysis, SWOT analysis, and others. Several trends and opportunities in major segments such as technology, specimen, product, application, end-user, and region are revealed by the study. The report also focuses on major insights which prove significance to key companies in terms of innovative approaches to strengthen their market position.

Get Sample Reporthttps://www.reportsinsights.com/sample/673786 

With increased global incidences of cancer, the demand for circulating tumor cells (CTC)-based diagnostics and therapeutics is also estimated to witness a significant increase among diagnostic centers and academic and research institutes.

The development of high-throughput screening and imaging technologies is expected to enable large-scale usage of CTCs detection and analysis with greater sensitivity and specificity in terms of advancements in technology.

Growing demand for customized or tailored medicine is anticipated to boost the sales of CTCs for the identification of tumor-specific biomarkers and the monitoring of treatment response.

Rising awareness about the ability of CTCs to detect cancer at an early stage, even before the onset of symptoms is expected to support the market expansion during the forecast period.

The integration of artificial intelligence (AI) in CTC-based diagnostics is anticipated to offer opportunities for the market players in the healthcare industry. The high demand for AI to improve the accuracy and efficiency of CTC-based diagnostics resulted in offering accurate and personalized cancer treatment.

Circulating Tumor Cells Market Report Coverage:-

Report Attributes Report Details
Market Size By 2030  USD 9.85 Billion
Forecast Period 2023-2030
CAGR (2023-2030) 12.3%
Base Year 2022
Study Timeline 2017-2030
Key Players Fluxion Biosciences Inc., Bio-Techne, Precision Medicine Group, LLC., QIAGEN, Aviva Systems Biology Corporation, BIOCEPT, Inc., Thermo Fisher Scientific, Greiner Bio One International GmbH, Ikonisys Inc., Miltenyi Biotec, IVDiagnostics, BioFluidica, Canopus Bioscience Ltd., Biolidics Limited, Creativ MicroTech, Inc., LungLife AI, Inc., Epic Sciences, Rarecells Diagnostics, ScreenCell, Menarini Silicon Biosystems, LineaRx, Inc. (Vitatex, Inc.), Sysmex Corporation, STEMCELL Technologies, Inc.
By Technology CTC Detection And Enrichment Methods (Immunocapture  (Label-Based) (Negative Enrichment, Positive Enrichment), Size-Based Separation (Label-Free) (Membrane-Based, Microfluidic-Based), Density-Based Separation (Label-Free), Combined Methods (Label-Free), Others) CTC Detection Methods (SERS, Microscopy, Others), CTC Analysis
By Specimen Blood, Bone Marrow, and Other Body Fluids
By Product Kits & Reagents, Blood Collection Tubes, Devices, or Systems
By Application Clinical/ Liquid Biopsy (Risk Assessment, Screening, and Monitoring), Research (Cancer Stem Cell & Tumorogenesis Research, Drug/Therapy Development)
By End Use Hospitals and Clinics, Diagnostic Centers, Research and Academic Institutes, Others
Report Coverage Company Ranking and Market Share, Growth Factors, Total Revenue Forecast, Regional Competitive Landscape, Business Strategies, and more.
By Geography North America [United States, Canada, Mexico]

Asia-Pacific [China, Southeast Asia, Japan, India, Korea, Western Asia]

South America [Brazil, Argentina, Columbia, Chile, Peru]

Europe [Germany, UK, Spain, Turkey, France, Italy, Russia, Netherlands, Switzerland]

Middle East & Africa [GCC, North Africa, South Africa]

Immediate Delivery Available, Buy Now @ https://www.reportsinsights.com/buynow/673786 

The development of CTC-based liquid biopsy assays is expected to offer opportunities for sustainable growth for the market of circulating tumor cells as liquid biopsy is a non-invasive method of cancer diagnosis and treatment monitoring. Such a method uses biofluids, specifically blood, to detect and analyze cancer biomarkers is anticipated to further boost the demand for CTCs that allow for early cancer detection, personalized treatment, and monitoring of treatment response.

The expansion of CTC-based diagnostics in oncology, including prognostic, predictive, and companion diagnostics is estimated to push forward the market growth during the forecast period. The high demand for CTC-based diagnostics to provide valuable information about cancer biology, treatment response, and disease progression is projected to accelerate market growth.

Collaboration and partnerships by major market players will lead to the development of new CTC-based technologies and therapies, as well as the validation of existing ones by innovations and technological advancements.

In terms of technology, CTC detection and enrichment methods are expected to witness a sudden increase in demand during the forecast period. By analyzing the genetic and molecular characteristics of CTCs, researchers can identify potential targets for new cancer treatments and develop more personalized approaches to cancer therapy with the help of such detection methods.

CTC detection and enrichment methods find major application in the post-treatment of minimal residual disease (MRD) and identification of specific biomarkers or genetic mutations in cancer cells. The main reason for such applications is due to the usage of CTC detection and enrichment methods in cancer research and clinical practice to identify and isolate cancer cells that have detached from the primary tumor and entered the bloodstream.

Key Market Takeaways

  • The global circulating tumor cells market size is expected to garner USD 9.85 billion by 2030 and expand at a CAGR of 12.3% during the forecast period (2023-2030).
  • Based on technology, the CTC detection and enrichment methods segment contributed the largest market share over 69.7% in 2022.
  • By specimen, the blood segment is anticipated to contribute the largest shares of the global circulating tumor cells market by 2030.
  • In the context of product, the devices or systems segment is projected to dominate the market statistics during the forecast period.
  • Based on application, the research segment is expected to lead the market growth with over 75.6% of the overall market shares.
  • By end use, diagnostic centers are expected to support the increased circulating tumor cells market statistics by 2030.
  • North America is projected to lead the market growth with excellent revenue shares due to access to astonishing healthcare infrastructure, including treatment facilities and advanced diagnostics.
  • With rising expenditures on research and development of new medical technologies by the government, Asia Pacific is also estimated to contribute substantial shares to the market growth over the forecasted period.

Circulating Tumor Cells Market Growth Drivers:

  • Increased investments by government and private organizations globally in research and development of CTC-based diagnostics and therapeutics result in the sustainable growth of the market for circulating tumor cells.
  • The development of new single-cell analysis technologies such as single-cell RNA sequencing boosts market statistics as the analysis allows for the identification of tumor-specific biomarkers, the monitoring of treatment response, and the development of new cancer therapies.
  • Growing usage of CTC-based assays in clinical trials drives the sales of such CTC to evaluate the efficacy of new cancer therapies.

Restraints

  • The risks of ethical concerns in terms of patient privacy and informed consent mainly limit the adoption of CTCs for diagnostics and treatments in case of their acceptance and usage in several settings.
  • The presence of alternative technologies such as liquid biopsy and next-generation sequencing that offer similar benefits as CTC-based diagnostics restricts the market share of CTC-based products.

Competitive Landscape

According to the Reports Insights, Menarini Silicon Biosystems, Epic Sciences, QIAGEN, Cynvenio Biosystems, and Biocept are expected to be leading market players along with other companies such as Fluxion Biosciences Inc., Miltenyi Biotec, ScreenCell, and Rarecells. The landscape of the circulating tumor cells market is constantly evolving as new companies enter the space and existing players expand their product offerings. There are also a number of academic and research institutions that are working on developing new technologies for the detection and analysis of CTCs, which is expected to potentially disrupt the existing market. Overall, the CTC market is highly competitive and is estimated to continue to grow as liquid biopsy of CTC becomes an increasingly important tool for cancer diagnosis and treatment.

Browse Full Report @ https://www.reportsinsights.com/industry-forecast/global-circulating-tumor-cells-market-statistical-analysis-673786 

Recent Developments

  • In October 2020, LungLife AI, a leading liquid biopsy technology company for cancer diagnosis and management, announced that they expect to publish clinical data related to a research collaboration on the early detection of lung cancer at the International Association for the Study of Lung Cancer (IASLC) Hot Topic Meeting.
  • In February 2021, Bio-Techne Corporation stated that their Exosome Diagnostics brand published a research paper titled “Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges” in the high-rated peer-reviewed journal Annals of Oncology. The paper provides unique insights into liquid biopsies, including CTC analysis and cfDNA, for cancer diagnosis.
  • In December 2021, Rarecells, Inc., a well-known liquid biopsy company specializing in non-invasive tests for early cancer diagnosis, declared that the business secured USD 5 million in funding, bringing the total Series A funding to USD 13 million. The funds will be used to support the launch of clinical operations and a laboratory in the United States which is focused on early detection tests for prostate cancer and acute myeloid leukemia.

List of Major Circulating Tumor Cells Market Players

• Fluxion Biosciences Inc.

• Bio-Techne

• Precision Medicine Group, LLC.

• QIAGEN

• Aviva Systems Biology Corporation

• BIOCEPT, Inc.

• Thermo Fisher Scientific

• Greiner Bio One International GmbH

• Ikonisys Inc.

• Miltenyi Biotec

• IVDiagnostics

• BioFluidica

• Canopus Bioscience Ltd.

• Biolidics Limited

• Creativ MicroTech, Inc.

• LungLife AI, Inc.

• Epic Sciences

• Rarecells Diagnostics

• ScreenCell

• Menarini Silicon Biosystems

• LineaRx, Inc. (Vitatex, Inc.)

• Sysmex Corporation

• STEMCELL Technologies, Inc.

• Cynvenio Biosystems

Global Circulating Tumor Cells Market Segmentation: 

  • By Technology
    • CTC Detection And Enrichment Methods
      • Immunocapture  (Label-Based)
        • Negative Enrichment
        • Positive Enrichment
      • Size-Based Separation (Label-Free)
        • Membrane-Based
        • Microfluidic-Based
      • Density-Based Separation (Label-Free)
      • Combined Methods (Label-Free)
      • Others
    • CTC Detection Methods
      • SERS
      • Microscopy
      • Others
    • CTC Analysis
  • By Specimen
    • Blood
    • Bone Marrow
    • Other Body Fluids 
  • By Product
    • Kits & Reagents
    • Blood Collection Tubes
    • Devices or Systems 
  • By Application
    • Clinical/ Liquid Biopsy
      • Risk Assessment
      • Screening and Monitoring
    • Research
      • Cancer Stem Cell & Tumorogenesis Research
      • Drug/Therapy Development
  • By End Use
    • Hospital and Clinics
    • Diagnostic Centers
    • Research and Academic Institutes
    • Others

Key Questions Covered in the Circulating Tumor Cells Market Report

What are the factors that drive the growth of market circumstances during the forecast period?

Which region is expected to account for the largest share contribution to the market statistics from 2023-2030?

What is the projected valuation of the circulating tumor cells market in 2030?

Which segment is expected to contribute the largest shares to the market growth from 2023-2030?

What are the market opportunities that will result in the sustainable growth of the circulating tumor cells industry over the forecasted period?

 Our Others Research Reports here:-

Hospital Asset Management Market Size, Share & Trends Analysis, By Product Type (Radio-Frequency Identification (RFID) Systems, Real-Time Location Systems (RTLS), Ultrasound and Infrared Sensors, Barcode Scanners, and Others), Application (Inventory Management, Equipment Tracking, Patient Tracking, Staff Management, Instrument Management, Supply Chain Management, and Others), End-User (Hospitals, Laboratories, Clinics, Ambulatory Surgical Centers, Pharmaceutical Companies, Biotechnology Companies, and Others), By Region, Forecast Period 2023 – 2030

Virtual Reality (VR) in Healthcare Market Size, Share & Trends Analysis, By Component (Hardware, Software, and Service), Technology (Full-Immersive, Semi-Immersive, and Non-Immersive), Application (Training and Education, Surgery, Patient Care Management, Rehabilitation & Adjunctive Therapy, Pain Management & Physical Therapy, and Medical Device Marketing), End Use (Hospitals & Surgical Centers, Research Organizations & Pharma Companies, Government & Defense medical Institutions, Research & Diagnostics Laboratories, and Others), Region and Segment, Forecast Period-2023 – 2030.

Virtual Reality Market Size, Share & Trends Analysis, By Component (Hardware and Software), Device Type (Head Mounted Display (HMD), Gesture Tracking Device, Projectors & Display Walls, and 3D Cameras), End-Use (Consumer Electronics, Healthcare, Retail, Education, and Others), By Region, Forecast Period 2023 – 2030.

Biopharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis, By Source (Mammalian and Microbial (Non-Mammalian)), Product Type (Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, Vaccines), Antisense, RNAi, & Molecular Therapy, Biosimilars), Service (Process Development, Fill & Finish Operations, Analytical & QC studies, Packaging), Therapeutic Area (Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Oncology, Neurology, Infectious Diseases, Respiratory Diseases, Others) By Region and Segment, Forecast Period 2023 – 2030

Bioelectronics Market Size, Share & Trends Analysis, By Type (Bio-Electronic Devices, Bio-Electronic Medicine), Product Type (Electrochemical Biosensors, Piezoelectric Biosensors, Others), Application (Fabrication Templates, Artificial Organs, Others), End User, Region and Segment, Forecast Period-2022 – 2030.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

Published

on

more-than-$9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024

Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.
TARRYTOWN, N.Y. and WASHINGTON, May 17, 2024 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Innovator Award, named in honor of the pioneering drug researcher and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer, in the 2024 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s largest pre-college science and engineering competition. Other top prizes went to projects in second-order cone programming, microplastics filtration and multi-sensory therapy for dementia.

The top winners were honored during two award ceremonies: the Special Awards on May 16 and the Grand Awards Ceremony on the morning of May 17. In total, over $9 million USD was awarded to the finalists based on their projects’ creativity, innovation and depth of scientific inquiry. The competition featured nearly 2,000 young scientists representing 49 U.S. states and nearly 70 countries, regions and territories across the world.
Grace Sun, 16, of Lexington, Kentucky, won first place and received the $75,000 George D. Yancopoulos Innovator Award for her research on building a better organic electrochemical transistor that she hopes will be used to develop new electronic devices that could help detect and treat serious illnesses like diabetes, epilepsy and organ failure. To overcome the problems that have previously prevented such devices from working effectively inside the body, Grace developed a new way of chemically treating their organic components, which greatly improved their laboratory performance.
Michelle Wei, 17, of San Jose, California, received one of two Regeneron Young Scientist Awards of $50,000 for her research to improve the speed and efficiency of a type of software that is useful in many fields such as machine learning, transportation and financial systems. Michelle’s new approach involved determining a quick approximate solution to the second-order cone programming problem, then splitting the initial cone into smaller cones, which enabled her new algorithm to greatly outperform previous approaches.
Krish Pai, 17, of Del Mar, California, received the second Regeneron Young Scientist Award of $50,000 for his machine-learning research to identify microbial genetic sequences that can be modified to biodegrade plastic. His new software, called Microby, scans databases of microorganisms and determines which ones can be changed genetically to biodegrade plastics. In tests, he identified two microorganisms that can be genetically modified to degrade plastic at a cost he believes would be ten times less than traditional recycling.
 “Congratulations to the Regeneron International Science and Engineering Fair 2024 winners,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “I’m truly inspired by the ingenuity and determination shown by these remarkable students. Coming from around the world with diverse backgrounds and academic disciplines, these students have shown that it is possible to come together in unity to tackle some of the toughest challenges facing our world today, and I could not be prouder.”
Regeneron ISEF provides a global stage for the world’s best and brightest young scientists and engineers. Through this competition, Regeneron and the Society are fostering the next generation of STEM leaders who are pioneering solutions to improve our world. Since 2020, Regeneron has provided STEM experiences to approximately 2.4 million students, on track to meet its goal of 2.5 million by 2025.
“The talent, intelligence and potential of this year’s Regeneron ISEF finalists is truly inspiring, and I congratulate each on their remarkable achievements,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron. “Science competitions like ISEF were pivotal in shaping my own career and fueling my passion to fight back against disease. I look forward to seeing these students continue to push the boundaries of science and technology to create positive and sustainable change for all humanity.”
Other top honors from the competition include:
Justin Huang and Victoria Ou, both 17, of Woodlands, Texas, received the Gordon E. Moore Award for Positive Outcomes for Future Generations of $50,000 for their new prototype filtration system that uses ultrasonic waves to remove microscopic plastic particles from water. In lab tests, the acoustic force from the high-frequency sound waves removed between 84% and 94% of the suspended microplastic particles in a single pass. The students are now working to scale up and fine-tune their experimental system.
Ingrid Wai Hin Chan, 17, of Hong Kong, China received the Craig R. Barrett Award for Innovation of $10,000 for her research on using a multi-sensory therapy for dementia patients. Her mixed therapy app would allow patients to practice physical and cognitive skills through a personalized, immersive environment using virtual reality headsets. Ingrid conducted an eight-week study with six people living with dementia and found that the cognitive function of patients who used her prototype improved in several areas. She believes her app could serve as a viable option for dementia patients with limited access to in-person professional therapy.
Tanishka Balaji Aglave, 15, of Valrico, Florida, received the H. Robert Horvitz Prize for Fundamental Research of $10,000 for her investigation into a natural alternative treatment against citrus greening, a disease that threatens citrus farming in many parts of the world and is currently only treated with antibiotics. Tanishka injected the trunks of infected trees with an extract from the curry leaf tree, and found through tests that this potential method could effectively and sustainably manage citrus greening disease.
Maddux Alexander Springer, 18, of Honolulu, Hawaii, received the Peggy Scripps Award for Science Communication of $10,000 for his research into fibropapillomatosis (FP), a disease that is the primary cause of death in green sea turtles. Some turtles he studied in Kaneohe Bay, Hawaii, were stricken with a disease that causes internal and external tumors that inhibit their everyday lives. After analyzing the turtles’ diet of green algae, Maddux concluded that this disease, wastewater, invasive algae and the amino acid arginine all pose a grave risk to these endangered sea creatures.
Ria Kamat, 17, of Hackensack, New Jersey; Anna Oliva, 17, of Houston, TX; and Shuhan Luo, 18, of Worcester, MA, received the Dudley R. Herschbach SIYSS Award, which provides finalists an all-expense paid trip to attend the Stockholm International Youth Science Seminar during Nobel Week in Stockholm, Sweden.
Jack Shannon, 18, of Clane, Kildare, Ireland, and Nikhil Vemuri, 17, of Cary, North Carolina, received the EU Contest for Young Scientists Award. Their projects will represent Regeneron ISEF at the EU Contest for Young Scientists to be held this September in Katowice, Poland.
For more information about the top winners and access to visual assets visit:  https://www.societyforscience.org/isef-2024-media-kit.
The full list of Special Award ISEF 2024 Finalists can be found at https://www.societyforscience.org/press-release/regeneron-isef-2024-special-awards-winners.
In addition to the Top Award winners, more than 450 finalists received awards and prizes for their innovative research, including “First Award” winners, who each received a $5,000 prize.
The following lists the First Award winners for each of the 22 categories, from which the Top Awards were chosen:
Animal Sciences, sponsored by Society for ScienceMaddux Alexander Springer, Honolulu, Hawaii
Behavioral and Social Sciences, sponsored by Society for ScienceAndrew Y. Liang, San Jose, California
Biochemistry, sponsored by RegeneronAmy Hong Xiao, Garden City, New York
Biomedical and Health Sciences, sponsored by RegeneronRia Kamat, Hackensack, New Jersey; Kevin Xuan Lei, Shanghai, China
Biomedical Engineering, sponsored by Alfred E. Mann CharitiesAyush Garg, Dublin, California; Divij Motwani, Palo Alto, California; Akash Ashish Pai, Portland, Oregon
Cellular and Molecular Biology, sponsored by RegeneronLara and Maya Sarah Hammoud, Beverly Hills, Michigan
Chemistry, sponsored by Society for ScienceAkilan Sankaran, Albuquerque, New Mexico; Arjun Suresh Malpani and Siddharth Daniel D’costa, Portland, Oregon
Computational Biology and Bioinformatics, sponsored by RegeneronKun-Hyung Roh, Bronx, New York
Earth and Environmental Sciences, sponsored by Google.orgNikhil Vemuri, Durham, North Carolina; Justin Yizhou Huang and Victoria Ou, The Woodlands, Texas
Embedded Systems, sponsored by HPChloe Rae and Sophie Rose Filion, Welland, Ontario, Canada
Energy: Sustainable Materials and Design, sponsored by Siemens EnergyAlia Wahban, Hamilton, Ontario, Canada
Engineering Technology: Statics and Dynamics, sponsored by Howmet Aerospace FoundationChiyo Nakatsuji, Bunkyoku, Tokyo, Japan; Kevin Shen, Olympia, Washington
Environmental Engineering, sponsored by JacobsKrish Pai, San Diego, California; Jack Shannon, Clane, Kildare, Ireland
Materials Science, sponsored by Howmet Aerospace FoundationGrace Sun, Lexington, Kentucky
Mathematics, sponsored by Akamai FoundationAnna Oliva, Houston, Texas
Microbiology, sponsored by Schattner FoundationMatthew Chang, Irvine, California
Physics and Astronomy, sponsored by Richard F. Caris Charitable Trust IIHarini Thiagarajan and Vishal Ranganath Yalla, Bothell, Washington; Shuhan Luo, Worcester, Massachusetts
Plant Sciences, sponsored by Society for SciencePauline Estrada, Fresno, California; Tanishka Balaji Aglave, Dover, Florida
Robotics and Intelligent Machines, sponsored by RegeneronMichal Lajciak, Dubnica nad Vahom, Trenciansky kraj, Slovakia; Anthony Efthimiadis, Oakville, Ontario, Canada
Systems Software, sponsored by MicrosoftMichelle Wei, San Jose, California
Technology Enhances the Arts, sponsored by Society for ScienceAnant Khandelwal, Sritan Motati and Siddhant Sood, Alexandria, Virginia
Translational Medical Science, sponsored by RegeneronZheng-Chi Lee, West Lafayette, Indiana; Ingrid Wai Hin Chan, Hong Kong, China
The full list of all award-winning ISEF 2024 finalists is available here: https://www.societyforscience.org/press-release/regeneron-isef-2024-full-awards.
View all the finalists’ research here: https://projectboard.world/isef.
About the Regeneron International Science and Engineering FairThe Regeneron International Science and Engineering Fair (Regeneron ISEF), a program of Society for Science for over 70 years, is the world’s largest global science competition for high school students. Through a global network of local, regional and national science fairs, millions of students are encouraged to explore their passion for scientific inquiry. Each spring, a group of these students is selected as finalists and offered the opportunity to compete for approximately U.S. $9 million in awards and scholarships.
In 2019, Regeneron became the title sponsor of ISEF to help reward and celebrate the best and brightest young minds globally and encourage them to pursue careers in STEM to positively impact the world. Regeneron ISEF is supported by a community of additional sponsors, including Akamai Foundation, Alfred E. Mann Charities, Aramco, Caltech, Google.org, Gordon and Betty Moore Foundation, Howmet Aerospace Foundation, HP, , Jacobs, King Abdulaziz & his Companions Foundation for Giftedness and Creativity, Microsoft, National Geographic Society, Richard F. Caris Charitable Trust II, Rise, an initiative of Schmidt Futures and the Rhodes Trust, Schattner Foundation, Siemens Energy, Annenburg Foundation, Ballmer Group, Broadcom Foundation, Cesco Linguistic Services, Conrad N. Hilton Foundation, Edison International, Insaco, Oracle Academy, The Eli and Edythe Broad Foundation, The Ralph M. Parsons Foundation and US Army ROTC. Many are entrepreneurs across a wide range of industries. Learn more at https://www.societyforscience.org/isef/.
About Society for ScienceSociety for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).
About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. 
Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
More information about the top winners and access to visual assets visit:  https://www.societyforscience.org/isef-2024-media-kit.
Media ContactsJoseph Brown, [email protected]
Gayle Kansagor, Society for [email protected]
Photo – https://mma.prnewswire.com/media/2416174/Regeneron_ISEF_2024_Winners_Photo.jpg 
Logo – https://mma.prnewswire.com/media/2416197/Society_for_Science_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/more-than-9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024-302149316.html

Continue Reading

Artificial Intelligence

J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Announce Winner of Inaugural 2024 Life Sciences Innovation Summit

Published

on

jp.-morgan-life-sciences-private-capital,-blue-horizon-advisors-and-united-al-saqer-announce-winner-of-inaugural-2024-life-sciences-innovation-summit

In conjunction with Abu Dhabi Global Healthcare Week 2024
ABU DHABI, UAE, May 17, 2024 /PRNewswire/ — J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Group announced today Rayees Rahman of Harmonic Discovery as the winner of the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. Harmonic Discovery is a precision pharmacology company applying its generative chemistry platform to advance next-generation kinase inhibitors.

In partnership with the Department of Health – Abu Dhabi (DoH), the Summit took place on May 14-15, 2024 at Cleveland Clinic Abu Dhabi and showcased the 11 innovative finalists, as well as highlighted existing innovators and opportunities in the Emirate of Abu Dhabi. The event also featured keynote speeches from Dr. Laurie Glimcher of Dana-Farber Cancer Institute, Dr. Shahrukh Hashmi of the Department of Health – Abu Dhabi, and Dr. David Ho of Columbia University Medical Center and provided attendees networking opportunities to gain valuable insights into the future of life sciences innovation. 
In addition, the jury designated Chun-Hao Huang of Algen Biotechnologies as honourable mention. Algen Biotechnologies is a platform therapeutics and drug discovery company using world-leading CRISPR and AI to find treatments for cancer, inflammation and metabolic diseases.
The winners were selected by an esteemed, international panel of judges, which included:Laurie Glimcher, MD, President and CEO at Dana-Farber Cancer InstituteJorge Guzman, MD, CEO at Cleveland Clinic Abu DhabiProf. Shahrukh Khurshid Hashmi, MD, Director of Research, Department of Health, Abu DhabiYasmine Hayek Kobeissi, PhD, CQF, BSc., Executive Director at Blue Horizon AdvisorsAnya Schiess, Managing Partner at J.P. Morgan Life Sciences Private CapitalWalid Zaher, PhD, Co-Founder and CEO, Carexso
Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi said: “Under the directives of the UAE’s wise leadership, and renowned for its world-leading medical infrastructure, Abu Dhabi stands at the forefront of healthcare excellence, offering an unparalleled opportunity for advancement in healthcare for global partners. It was our utmost pleasure hosting the J.P. Morgan Asset Management Life Sciences Innovation Summit 2024 on the sidelines of Abu Dhabi Global Healthcare Week and we commend the winners for their pioneering efforts in driving impactful advancements in healthcare; their dedication to innovation not only transforms the landscape of medicine, but also holds the promise of improving lives worldwide.” 
Stephen Squinto, PhD, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital said: “We are thrilled with the level of biotech passion and innovation that we observed at this year’s Summit in Abu Dhabi. The energy was truly palpable we are thrilled to announce Rayees Rahman as the winner of our first Life Sciences Innovation Summit. Harmonic Discovery’s approach embodies the next generation of drug discovery and development. We appreciate the time and effort of all participants and cannot wait for our next event in the region.”
Nabil Kobeissi, Chief Executive Officer of Blue Horizon Advisors, said: “As the main sponsor, we are committed to nurturing and fostering the growth of all 11 finalists in this vibrant biotech ecosystem. This Summit marks the beginning of a transformative journey, and we are confident that it will pave the way for a flourishing hub in the region. We are also pleased to announce that we will commit to invest in and partner with the winner, Harmonic Discovery, to support its future growth in the region.”
Sponsors for the event included J.P. Morgan Life Sciences Private Capital, J.P. Morgan Commercial Bank, Blue Horizon Advisors, United Al Saqer Group, Thermo Fisher Scientific, and Salam Capital. The Summit organisation, logistics and finalist recruitment were facilitated by Lyfebulb.
Of importance, at the Summit, Mr. Mohamed Al Breiki, Executive Director of Sustainable Development at Masdar City, announced that Masdar City Free Zone would award all 11 Finalists complimentary business licenses to further support their establishment in the region. Masdar City is one of the world’s most sustainable urban developments and innovation hubs with a growing focus on life science entrepreneurship in Abu Dhabi.

View original content:https://www.prnewswire.co.uk/news-releases/jp-morgan-life-sciences-private-capital-blue-horizon-advisors-and-united-al-saqer-announce-winner-of-inaugural-2024-life-sciences-innovation-summit-302149186.html

Continue Reading

Artificial Intelligence

Congregating in the Lion City for a Win-Win Future of Intelligent Computing at the Global Data Center Facility Summit 2024

Published

on

congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024

SINGAPORE, May 17, 2024 /PRNewswire/ — On May 17, 2024, the Global Data Center Facility Summit 2024 was held in Singapore with the theme of “Power the Digital Era Forward.” At the summit, over 600 data center industry leaders, technical experts, and ecosystem partners gathered to discuss new trends and opportunities of the global data center industry in the intelligent computing era. The attendees also got to experience all-scenario, all-ecosystem, and all-service end-to-end (E2E) solutions, share innovative practices of green data centers in the Asia Pacific and Europe, and experience the exhibition vehicle to unveil the mystery of Outdoor PowerPOD that features one power system per container. By fully embracing the intelligent computing era, Huawei strives to power the digital era forward.

Seizing Opportunities Brought by AI and Jointly Building Green & Reliable Computing Infrastructure
At the opening speech, Charles Yang, Senior Vice President of Huawei and President of Marketing, Sales and Services, Huawei Digital Power, noted that since ChatGPT ushered in the AI era, large models keep pushing the limits of computing power and the intelligent computing industry is witnessing an unprecedented construction boom. As predicted, 100 GW will be added to the global data center installed capacity and the market value will exceed US$600 billion in the next five years.
According to Charles, with opportunities come challenges. The primary challenge concerning the data center industry is reliability and electricity. Data centers are scaling up from the MW-level to the GW-level. E2E reliability of data centers is becoming even more important than ever. In response to the opportunities, Huawei will work with customers and partners to expand the industry space.
Steering Data Centers to the AI Era with Product + Service + Ecosystem
During the summit, Sun Xiaofeng, President of Huawei Data Center Facility & Critical Power Business, delivered a speech titled “Power the Digital Era Forward. ” He stated that as AI large models are penetrating, the surging compute demands drive the expansive growth in data center.
To address the challenges, Huawei strives to build product + service + ecosystem E2E data center solutions that feature fast deployment, flexible cooling, green energy, and ultimate reliability.
Fast deployment: Data centers are fully modularized and prefabricated to ensure high quality and efficient construction.Flexible cooling: Air-liquid fusion and integrated cooling source emerges as the optimal cooling architecture for intelligent computing.Green energy: New generation-grid-load-storage integrated solution is built to ensure the sound operations of intelligent computing centers.Ultimate reliability: Data centers are safeguarded through reliable products and preventive protection.Currently, Huawei’s global service network covers more than 170 countries with over 1800 professional engineers, providing 24/7 technical support. With N+ flagship service centers, Huawei has built a one-hour service radius for its customers.
The ecosystem is a key part for a win-win future of intelligent computing. Huawei works with partners to develop comprehensive E2E solutions and provide customers with one-stop data center services.
During the summit, Huawei and the ASEAN Centre for Energy released a white paper on “Building Next Generation Data Center Facility in ASEAN.” The document provides insights into the status quo, challenges, and trends of data centers in the ASEAN region, and emphasizes that efficient and energy-saving products and solutions should be applied. It also proposes future-oriented policy recommendations for data center markets.
In the ecosystem exhibition area, Huawei showcased scenario-based solutions for large-, medium-, and small-sized data centers, and demonstrated data center consulting, design, integrated development, and delivery capabilities with dozens of ecosystem partners including CIMC, Weichai, CSCEC, and Huashi.
On a special note, the Huawei Outdoor PowerPOD exhibition vehicle made its global debut. The Huawei Outdoor PowerPOD features one power system per container, outdoor deployment, plug-and-play, and high protection rating and reliability. It has become the preferred choice for decoupling the power supply architecture.
A single tree cannot make a forest.
AI is presenting great opportunities. By delving into the industry, aggregating partner ecosystems, and making innovations applicable to transformations, Huawei will continue to help customers build reliable computing infrastructure, accelerating the industry to embrace AI and powering the digital era forward.
Photo – https://mma.prnewswire.com/media/2415818/Global_Data_Center_Facility_Summit_2024.jpg

View original content:https://www.prnewswire.co.uk/news-releases/congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024-302148973.html

Continue Reading

Trending